osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
plenary: adaura -os update here we are, 3 years after the initial adaura plenary (and many discussions on pfs being a strong enough endpoint), we now see the os benefit of 3 years of adjuvant osimertinib after resected, stage 1b-3a egfrmt nsclc. hr:0.49!
confirms soc
#asco23 
Medical Oncologist. Chief of Hem/Onc, PD of hem/onc fellowship, Dr Peter White Endowed Professor, & Associate Professor at The University of Toledo.